People who could have had more good years simply didn't receive the therapies that could have made that happen.
Each year, roughly fifty thousand Americans diagnosed with advanced lung cancer never receive treatment — not because medicine has failed to find answers, but because the answers are not reaching them. A study published in JAMA Oncology by researchers at MUSC Hollings Cancer Center reveals that the gap lies not in the oncology clinic, where treatment rates are high, but in the long and often broken path that leads there. It is a story about the distance between what medicine knows and what medicine does — a distance measured, in this case, in human lives.
- Despite therapies that can extend survival by up to seven years, half of all metastatic lung cancer patients in the U.S. — roughly 50,000 people annually — never receive a single treatment.
- The crisis is not inside oncology clinics, where 80–90% of patients who arrive do get treated; it is in the referral void where tens of thousands are diagnosed and then simply never sent to a specialist.
- Outdated fears rooted in the brutal chemotherapy of decades past, lack of transportation, under-resourced hospitals, and the absence of family support are all keeping patients from the door.
- Clinical trial criteria designed for healthier patients have shaped treatment guidelines that exclude many who could now tolerate modern immunotherapies with far fewer side effects.
- Over a fifteen-year study period spanning oncology's most transformative era, the proportion of patients receiving any treatment barely moved — a finding researchers describe as deeply unimpressive.
- The path forward demands earlier diagnosis, faster referrals, and a public reckoning with how profoundly lung cancer treatment has changed — before another generation of patients decides not to try.
A study published this week in JAMA Oncology landed on a number that startled even its own authors: roughly half of all Americans diagnosed with metastatic non-small-cell lung cancer never receive any treatment. This is not a failure of science. Over the past two decades, oncology has produced targeted drugs and immunotherapies that extend survival by as much as seven years and meaningfully improve quality of life. Yet fifty thousand people a year are diagnosed with advanced lung cancer and sent home without ever accessing them.
Gerard Silvestri and Adam Fox, pulmonologists at MUSC Hollings Cancer Center, set out to study biomarker testing rates — the genetic screening that matches drugs to tumors — but quickly realized they needed to answer a more fundamental question first: how many patients were being treated at all? When they surveyed colleagues, most oncologists guessed eighty to ninety percent. The data told a different story.
The gap was not inside the oncology clinic. Among patients who actually reached a medical oncologist, treatment rates were indeed that high. The problem was upstream: many patients were diagnosed — sometimes by a primary care physician, sometimes in an emergency room — and never referred onward. The researchers have preliminary theories about why. Some patients carry memories of a parent's brutal chemotherapy and assume modern treatment is no different. Some lack transportation or family support; the study found married patients were significantly more likely to receive treatment. And clinical trial criteria, built around relatively healthy patients, have produced guidelines that exclude many who could now tolerate the gentler side-effect profiles of immunotherapy.
The numbers are unsparing. Of the roughly one hundred thousand Americans diagnosed with metastatic lung cancer each year, only half receive treatment. Forty percent of all patients in the study were dead within ninety days of diagnosis — a reminder that time is not a renewable resource in this disease. The researchers believe a meaningful share of the untreated were genuine candidates who simply never got the referral, never got the conversation, never got the chance.
What makes the finding especially sobering is its persistence. Across the fifteen-year study period — 2006 to 2021, spanning oncology's most transformative era — the proportion of patients receiving treatment barely changed. The researchers' message to the medical community is direct: diagnose earlier, refer faster, and tell patients clearly that the treatments available today are not the treatments their parents endured. The science has moved. The system, so far, has not kept up.
A study published this week in JAMA Oncology arrived at a number that stopped the researchers who uncovered it: roughly half of all Americans diagnosed with metastatic non-small-cell lung cancer never receive any treatment at all. This is not because the treatments don't work. Over the past two decades, oncology has developed therapies—targeted drugs for specific genetic mutations, immunotherapies that harness the immune system—that have extended survival by as much as seven years and dramatically improved quality of life. Yet in a health system with these tools available, fifty thousand people a year are diagnosed with advanced lung cancer and sent home without ever receiving them.
Gerard Silvestri and Adam Fox, both pulmonologists at MUSC Hollings Cancer Center, led the research on behalf of the American Cancer Society National Lung Cancer Roundtable. They began with a different question entirely: how many patients were actually getting biomarker testing, the genetic screening that allows doctors to match a drug to a tumor's specific mutations? But before they could answer that, they realized they needed to know something more basic. How many patients were getting treated at all? When they asked colleagues across the country, most oncologists guessed eighty to ninety percent. The data told a different story.
The gap, it turned out, was not in the oncology clinic. Among patients who actually made it to a medical oncologist—especially one at a specialty cancer center—treatment rates were indeed in that eighty to ninety percent range. The problem lay upstream. Many people with metastatic lung cancer never saw an oncologist in the first place. They were diagnosed, perhaps by a primary care doctor or in an emergency room, and then simply did not get referred. The researchers are now planning follow-up work to understand why, but they have preliminary theories based on their clinical experience.
One is perception. Patients remember what happened to their parents. Lung cancer treatment thirty years ago was brutal—chemotherapy with severe side effects and minimal survival benefit. That memory is not wrong, but it is outdated. The newer drugs are fundamentally different. Yet this message has not penetrated widely, either among patients or among some clinicians. Another barrier is practical: lack of transportation, care at under-resourced hospitals, absence of family support. The study found that married patients were more likely to receive treatment, a finding that aligns with existing research on how social support shapes medical outcomes. A third is clinical trial design. Treatment guidelines come from trials that enrolled relatively healthy patients, on the theory that sicker people cannot tolerate toxic drugs. But immunotherapies have far fewer side effects than traditional chemotherapy, which means a much larger pool of patients—including those with multiple chronic conditions—could potentially benefit.
The numbers are stark. More than two hundred thousand Americans will be diagnosed with lung cancer this year. About one hundred thousand of those cases will be metastatic at the time of diagnosis. Only fifty thousand will receive treatment. Forty percent of all patients in the study were dead within ninety days of diagnosis, which underscores why early detection and rapid referral matter so much. A patient who is too sick to tolerate treatment by the time they are diagnosed cannot be helped, no matter what drugs exist. But the researchers believe a significant minority of the untreated patients were actually suitable candidates—people who could have had more time, more good days, more moments with family. They simply never got the chance.
The increase in treatment rates over the fifteen-year study period, from 2006 to 2021, was what Fox called "unimpressive." This span covered the transition from chemotherapy as the standard of care to the era of immunotherapy and targeted drugs. Yet the proportion of patients receiving any treatment barely budged. The researchers say the message to the medical community is clear: diagnose early, refer quickly, and tell patients that treatments exist that can extend both survival and quality of life. The work of implementation, they acknowledge, has only just begun.
Notable Quotes
The thing we really wanted to look at was the prevalence of biomarker testing. But before we look at how many people get tested, we should start to know how many people even get treated.— Dr. Adam Fox, MUSC Hollings Cancer Center
Get patients to an oncologist—quickly—so that we can see if they're eligible for one of these new treatments.— Dr. Gerard Silvestri, MUSC Hollings Cancer Center
The Hearth Conversation Another angle on the story
Why does it matter that half these patients never see an oncologist? Couldn't their primary care doctor prescribe the same drugs?
Oncologists know which patients are candidates for which treatments. They understand the biomarkers, the side effect profiles, the sequencing of drugs. A primary care doctor might not have that expertise, and by the time they think to refer, the patient is too sick.
So this is really a referral problem, not a treatment problem?
It's both. But yes—the study shows that if you make it to an oncologist, your odds are good. Most people never make that journey. They get diagnosed and then fall out of the system.
The study mentions that forty percent of patients die within ninety days. How many of those were actually treatable?
That's what they're trying to figure out next. Some were too sick. But the researchers believe a meaningful number could have benefited from treatment if they'd been referred faster and gotten a full workup.
What about the outdated perception problem—patients remembering their parents' bad experiences with chemotherapy?
That's a communication failure. Modern drugs are completely different. Some extend survival by seven years. But if nobody tells patients that, they assume treatment means suffering with no benefit, just like it did decades ago.
Is this a problem unique to lung cancer?
Lung cancer is the deadliest cancer in America. But the barriers—referral gaps, outdated perceptions, lack of social support—probably exist across oncology. This study just quantified it clearly for the first time.